Almost all humans are latently IgG-seropositive for the double-stranded DNA human herpesvirus 5 named cytomegalovirus (CMV). CMV is an AIDS-defining World Health Organization (WHO) stage 4 opportunistic infection for both adults and children, seen when the CD4 T-cell count falls below 100 cells/µl and as an immune reconstitution syndrome after starting highly active antiretroviral therapy (HAART).  

**CLINICAL MANIFESTATIONS**

Active CMV disease may present multi-systemically, with significant morbidity and mortality. Organ system manifestations include:

**CMV retinitis (CMV-R).** This is a visual emergency usually presenting with blurred vision, floaters, black spots, flashing lights, distortions, redness and photophobia, but sometimes asymptomatic. WHO clinical diagnosis guidelines for CMV-R include dilated pupil indirect fundoscopic identification of 'discrete patches of retinal whitening with distinct borders, spreading centrifugally, often following blood vessels, associated with retinal vasculitis, haemorrhage and necrosis.' Figs 1 and 2 show CMV-R before and after local treatment, respectively. This fundoscopic picture is known as the 'pizza pie' appearance. CMV-R may result in blindness.

**CMV of the gastro-intestinal tract.** Colitis is symptomatic as chronic watery diarrhoea that may become bloody, and oesophagitis symptomatic as dysphagia, anorexia and weight loss. Hepatitis may occur, and there are reports of acalculous cholecystitis.

**CMV adrenalitis.** Adrenal insufficiency may manifest as postural hypotension, fatigue, hypernatraemia, hyperkalaemia and acidosis. It has a high mortality rate.

**CMV pneumonitis.** Manifestations are tachypnoea, hypoxia and dry cough, which are commonly misdiagnosed as Pneumocystis jirovecii pneumonia.
CMV of the neurological system. Encephalitis presents with headache, subacute personality changes, decreased concentration, and progressive dementia. Transverse myelitis may occur. CMV is a recognised cause of acute inflammatory demyelinating polyradiculopathy (Guillain-Barré syndrome), the hallmarks of which are rapidly progressive ascending and often asymmetrical paraesthesiae, sensory loss and areflexia, as well as urinary retention, constipation and incontinence. The cerebrospinal fluid may demonstrate polymorphonucleocytosis and raised protein, and the diagnostic method of choice is polymerase chain reaction (PCR) testing of the cerebrospinal fluid for CMV DNA.

SOUTH AFRICAN SPECTRUM OF DISEASE

Most data for CMV in the developed world were established in the 1990s, before the HAART era. CMV-R was found in a third of AIDS patients, with a large resulting burden of blindness. In one pre-HAART Swiss study of 48 patients, median survival after CMV retinitis was 6 months. HAART improved survival markedly in AIDS CMV-R patients.

There is a paucity of CMV data in the developing world. CMV has been called the ‘neglected disease of the AIDS pandemic’ because of poor diagnostic and treatment capability. In South Africa’s pre–HAART era, 90 AIDS patients were treated for CMV-R at the University of Natal over 7 years, and the incidence was noted to increase with time. A cross-sectional study screening all HIV-infected patients with CD4 counts <50 cells/µl in Khayelitsha, South Africa, diagnosed CMV-R in 2% of these patients using diluted pupil indirect ophthalmoscopy. In a South African autopsy study of 47 HIV-infected cadavers where the clinician-attributed cause of death had been tuberculosis, CMV pneumonitis was proven in 15% and 66% tested positive for CMV-DNA.

South Africa has both a high burden of HIV disease and a large, expanding HAART programme. Many South African HIV-infected patients present for initiation of HAART when the CD4 count is less than 100 cells/µl, and often the median is less than 50 cells/µl, which makes them susceptible to CMV disease. The return to health and longevity that HAART confers shapes a powerful argument to treat CMV efficiently and prevent its debilitating effects.

DIAGNOSTIC OPTIONS

A variety of testing options exist to identify active systemic CMV infection (Table I). Viral culture is traditionally accepted as the ‘gold standard’ method of detection. Simpler and more rapid options are now proving as or more effective. The pp65 antigen assay can provide very sensitive results in less than 6 hours, the main drawback being the need for immediate sample processing after retrieval in order to ensure test validity. Serological tests for the presence of IgM and IgG antibodies may have little diagnostic value in the immunocompromised patient.

CMV DNA-PCR tests provide sensitive results that can reproducibly quantify CMV viral loads. In HIV-infected patients, both DNA-PCR and pp65 antigen assay have proven to be more predictive in detecting CMV than serology or viral culture. The CMV pp67 mRNA test is a promising new method used in research settings.

TREATMENT: THE URGENT NEED FOR VALGANCICLOVIR PRICE REDUCTION IN SA FOR CMV TREATMENT IN HIV PATIENTS

CMV treatment strategies (Table II) include systemic and local products, the latter for ophthalmological indications. After completion of an induction phase, patients remain on maintenance therapy until immune recovery (CD4 >100 cells/µl).

Because southern African health facilities are poorly resourced, widespread use of intra-ocular ganciclovir (GCV) is not feasible. Specialist ophthalmological services are scarce in the state sector, and sometimes non-existent in rural areas. Intra-ocular GCV may not always be acceptable to patients, and is not without procedure-related adverse effects such as endophthalmitis. Most importantly, intra-ocular GCV does not prevent spread of CMV to the other eye, and completely fails to treat disseminated CMV.

Unfortunately, the exorbitant cost of systemic CMV treatments is prohibitive in the state sector. Systemic GCV necessitates a 3-week stay in hospital for intravenous induction, followed by oral maintenance GCV. Lengthy intravenous induction is not always realistic in resource-poor settings and may place
### TABLE I. CMV Diagnostic Tests

<table>
<thead>
<tr>
<th>Test</th>
<th>Tube/transport</th>
<th>Samples</th>
<th>Volume required</th>
<th>Turnaround time</th>
<th>Price estimate (2009)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMV viral culture (shell vial)</td>
<td>No preservative</td>
<td>Urine, CSF aspirate, blood not an ideal sample</td>
<td>1 ml</td>
<td>2 - 7 d (state), 3 - 28 d (pvt)</td>
<td>R82 (state), R97.11 (pvt)</td>
</tr>
<tr>
<td>CMV pp65 antigen (IFA)</td>
<td>EDTA, room temperature, must be received at NICD before 14h00 same day as collection</td>
<td>Whole blood Result may be impossible if patient neutropenic</td>
<td>5 ml</td>
<td>1 - 3 d</td>
<td>R171 (state), R182.97 (pvt)</td>
</tr>
<tr>
<td>CMV IgG and IgM</td>
<td>Yellow-top</td>
<td>Blood (serum)</td>
<td>1 d</td>
<td>IgG R104.85 (pvt), IgM R113.76 (pvt)</td>
<td></td>
</tr>
<tr>
<td>Qualitative CMV DNA-PCR</td>
<td>EDTA</td>
<td>Any sample including blood, CSF, etc.</td>
<td>1 d</td>
<td>R607.14 (pvt)</td>
<td></td>
</tr>
<tr>
<td>Quantitative CMV DNA-PCR (i.e. CMV viral load)</td>
<td>EDTA</td>
<td>Whole blood</td>
<td>1 d</td>
<td>R1 214.18 (pvt)</td>
<td></td>
</tr>
</tbody>
</table>

pvt = estimated prices courtesy Toga Laboratories; state = estimated prices courtesy NHLS/NICD.

### TABLE II. CMV Treatment in Adults

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>Price estimates across sectors</th>
<th>Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Private</td>
<td>State</td>
</tr>
<tr>
<td>Valganciclovir (Valcyte; Roche)</td>
<td>Initiation phase</td>
<td>900 mg bd po with meals × 21 days</td>
<td>R24 719.87 for 21 days</td>
</tr>
<tr>
<td></td>
<td>Maintenance phase</td>
<td>900 mg/d po with meals until HAART restores CD4 count &gt;100 cells/µl</td>
<td>R17 657.05 per month</td>
</tr>
<tr>
<td>No generics currently available in South Africa</td>
<td>Induction phase: intravenous</td>
<td>5 mg/kg IV bd × 21 days</td>
<td>R2 558.24 for 5 vials</td>
</tr>
<tr>
<td></td>
<td>Maintenance phase: oral</td>
<td>1 g tds po</td>
<td>Oral ganciclovir is not available in South Africa Suggest maintenance with valganciclovir</td>
</tr>
<tr>
<td>Ganciclovir (Cymevene; Roche)</td>
<td>Inj.: 500 mg in 10 ml vials ×5 Caps: 250 mg (84), 500 mg (90)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>No generics currently available in South Africa</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Local treatment for CMV retinitis</td>
<td>In a recumbent patient, 2 mg of a 25 mg/ml ganciclovir solution in normal saline is injected with a 1 ml syringe and 30G needle, 4 mm behind the limbus of the eye superiorly with the patient looking down. Patients are given intravitreal ganciclovir injections twice a week for the first 2 weeks, then weekly until immune recovery or retinitis quiescence</td>
<td></td>
</tr>
</tbody>
</table>

*Minimum order of CHF 10 000. Each 60-tab box of 450 mg tablets costs CHF 500, plus freight and insurance changes apply (estimated CHF 177.40 + 40.20 respectively for a 26-box order) (CHF = Swiss franc, 1 CHF = 7.47309 ZAR, exchange rate at 1 June 2009). NGO orders can be placed only at Roche Basle (sandra.tomlani_cazzato@roche.com). The lead time is 3 months after receipt of firm order. Prices quoted are per Roche, May/June 2009.

*Minimum order of CHF 10 000. Each 60-tab box of 450 mg tablets costs CHF 500, plus freight and insurance changes apply (estimated CHF 177.40 + 40.20 respectively for a 26-box order) (CHF = Swiss franc, 1 CHF = 7.47309 ZAR, exchange rate at 1 June 2009). NGO orders can be placed only at Roche Basle (sandra.tomlani_cazzato@roche.com). The lead time is 3 months after receipt of firm order. Prices quoted are per Roche, May/June 2009.

FBI = full blood count; AZT = zidovudine.
immune-compromised patients at risk of contracting nosocomial illnesses.

The benefits of valganciclovir are evident: it is taken orally, easy to administer in resource-poor settings, well tolerated, and efficacious in both induction and maintenance phases of treatment. Its cost currently prevents its use in South African CMV AIDS patients.

Second-line intravenous treatment options such as foscarin and cidofovir are avoided because of nephro-toxicity.

**PAEDIATRIC CMV TREATMENT AND PREVENTION IN PREGNANCY**

Congenital CMV causes a broad range of neurodevelopmental deficits in both symptomatic and initially asymptomatic neonates, including microcephaly, choriorretinitis and sensorineural hearing loss.

A 6-week course of intravenous ganciclovir has been shown to be effective in preventing hearing loss, improving weight gain and head circumference, and resolving hepatic dysfunction, hepatomegaly and retinitis. Ganciclovir toxicity, especially neutropenia, can however be life-threatening.

Results of a small pharmacokinetic study show that oral valganciclovir at a dose of 16 mg/kg provided similar plasma levels of drug compared with 6 mg/kg intravenous ganciclovir, so it appears that valganciclovir is a promising option for treating neonatal and paediatric patients.

Vertical CMV transmission is trans-placental, and the rate is observed to be higher in HIV-1-infected mothers. Infants who are co-infected with HIV-1 and CMV are more likely to have rapid HIV disease progression.

Valganciclovir and ganciclovir are both considered potentially teratogenic from animal data, but there are no controlled studies in pregnant women.

A recent development in March 2009 is a CMV vaccine that may offer future public health benefits for pregnant women by eliminating CMV.

**HOW CAN VALGANCICLOVIR PRICE REDUCTION BE ACHIEVED IN SOUTH AFRICA?**

Currently, the cost of CMV treatment makes it unaffordable to most.

Letters of concern on behalf of the South African HIV Clinicians Society have been sent to Roche urging price reduction of CMV treatments in the sub-Saharan African region. Various organisations internationally are lobbying for price reduction, including Médecins Sans Frontières, Universities Allied for Essential Medicines and the Clinton HIV/AIDS Foundation.

Valganciclovir for CMV treatment in AIDS patients must be placed on our state tender request list. Currently it is available through state discretionary funds to transplant patients only. Government should consider compulsory licensing for price-slashed generic production of valganciclovir for the state sector.

**REFERENCES**